Ark Clinical Research

Summary

Ark Clinical Research is a medical facility located in Long Beach, California. This center is recognized for care of I Am A Healthy Volunteer, Type 2 Diabetes, Coronavirus, Flu, COVID-19 and other specialties. Ark Clinical Research is involved with conducting 38 clinical trials across 58 conditions. There are 4 research doctors associated with this hospital, such as Apinya Bee Vutikullird, Kenneth T Kim, Apinya Vutikullird, DO, and Justin Yanuck, MD.

Top PIs

Clinical Trials running at Ark Clinical Research

Cardiovascular Disease

Type 2 Diabetes

Obesity

Fatty Liver Disease

Chronic Urticaria

Liver Fibrosis

Atherosclerosis

Chronic Obstructive Pulmonary Disease

Hypertriglyceridemia

Asthma

Lepodisiran

for Cardiovascular Disease

This trial is testing lepodisiran, a medication given as an injection under the skin. It targets people with high levels of lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke. The medication works by lowering lipoprotein(a) levels to reduce the risk of these cardiovascular events.

Recruiting

1 award

Phase 3

Vicadrostat + Empagliflozin

for Type 2 Diabetes and Hypertension

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruiting

1 award

Phase 3

4 criteria

Retatrutide

for Obesity

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

Recruiting

1 award

Phase 3

2 criteria